comparemela.com

Page 6 - Abionyx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3 60 Per Share to Become a Specialist of Bioproducts

IRIS Pharma becomes a subsidiary of ABIONYX Pharma and remains independent in its service activities for major pharmaceutical and biotech companies in the ophthalmology sector A potential

United statesJean louis dasseuxLuc demarreYann quentricPierre paul elenaArthur rouillIris pharmaCyrille tupinChristian chavyLouis victor delouvrierM emmanuel huynhSadok belmokhtarPharma holdingIris pharma holdingFully compensatedNew shares

ABIONYX Pharma: ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3 60 Per Share

Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients

United statesJean louis dasseuxLuc demarreEmmanuel huynhArthur rouillIris pharmaCyrille tupinChristian chavyLouis victor delouvrierPharma holdingRegulatory newsChief executive officerFrench monetaryFinancial codeGeneral meetingRegistration document

ABIONYX Pharma Announces Its Cash Position and Provides an Activity Update for the 3rd Quarter 2021

Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible) (Paris:ABNX) a next-generation biotech company dedicated to the discovery and development of innovative therapies, announces

France generalArthur rouillLouis victor delouvrierRegulatory newsTemporary use authorizationVictor delouvrier

ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal

Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 ABNX PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced

Arthur rouillLouis victor delouvrierRegulatory newsTemporary use authorizationVictor delouvrier

ABIONYX Pharma Announces Positive Preclinical Results in a Model of Uveitis and Launches the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its bio-HDL

Positive preclinical results in a model of uveitis Development of the first class of biomedicines in ophthalmology with bio-HDL Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852

United statesFrance generalCatherine creuzot garcherLouis victor delouvrierNicolas merigeauChristophe baudouinOphthalmologica internationalisAmerican society of ophthalmologyCentre hospitalier nationalFood science centerHead of the ophthalmology departmentUniversity hospital of dijonEuropean medicines agencyUniversity professorOrphan drugTemporary use authorization

vimarsana © 2020. All Rights Reserved.